GWYN LO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gwyn Lo, and what generic alternatives are available?
Gwyn Lo is a drug marketed by Viatris Specialty and is included in one NDA.
The generic ingredient in GWYN LO is ethinyl estradiol; norelgestromin. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gwyn Lo
A generic version of GWYN LO was approved as ethinyl estradiol; norelgestromin by AMNEAL on February 25th, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GWYN LO?
- What are the global sales for GWYN LO?
- What is Average Wholesale Price for GWYN LO?
Summary for GWYN LO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in GWYN LO? | GWYN LO excipients list |
| DailyMed Link: | GWYN LO at DailyMed |
US Patents and Regulatory Information for GWYN LO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris Specialty | GWYN LO | ethinyl estradiol; norelgestromin | SYSTEM;TRANSDERMAL | 219990-001 | Jul 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
